-
Cost-Effectiveness Analysis of Serplulimab Combined with Nab-Paclitaxel Plus Carboplatin Compared to Nab-Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer in China
14 Apr 2025 14:59 GMT
… of ASTRUM-004 trial, serplulimab combined with … ). Drug costs were derived from the Jiangsu Pharmaceutical Medical Consumables … combined with docetaxel as the second-line treatment. This … evaluations alongside clinical trials--extrapolation with patient- …
-
Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study.
14 Apr 2025 13:46 GMT
… [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we … severe AEs associated with these treatment regimens.
In this retrospective, multicenter … , The Jikei University School of Medicine, Tokyo, Japan.
PubMed http:…
-
Comparative Analysis of Clinical Efficacy and Safety of Pyrotinib Plus Capecitabine versus Trastuzumab Emtansine (T-DM1) as Second-Line Treatment for HER2-Positive Advanced Breast Cancer: A Retrospective Study
14 Apr 2025 06:23 GMT
… trial indicated that the combination of trastuzumab, pertuzumab, and docetaxel … the Food and Drug Administration (FDA) was Trastuzumab … medication due to side effects. Furthermore, neither treatment … drug availability and distribution.
Recent clinical trials …
-
Infinitopes granted phase I/IIa clinical trial application approval
10 Apr 2025 16:03 GMT
… Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial … oxaliplatin, and docetaxel) chemotherapy. Infinitopes’ VISTA trial will be … the UK Clinical Trials Registry for Integrated … need better, affordable treatments for the disease. …
-
Exploration of Traditional Chinese Medicine Comprehensive Treatment of Triple Negative Breast Cancer Based on Molecular Pathological Mechanism
09 Apr 2025 22:37 GMT
… the PATTERN trial indicated that anthracycline-free treatment regimens … carboplatin as opposed to docetaxel.82 Furthermore, it … B; FDA, Food and Drug Administration; TCM, traditional Chinese medicine; TAM … pathway. Appl Biochem Biotechnol. 2023;195(4): …
-
Expanded FDA Approval Broadens the Role of Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
09 Apr 2025 21:45 GMT
… refused or the doctor and patient agreed … 177 vipivotide tetraxetan or docetaxel [in this setting]. … s disease, characteristics, previous treatments, response [to prior therapy … ;www.fda.gov/drugs/;resources-information-approved-drugs/fda-expands- …
-
Relmada Therapeutics To Present NDV-01 Data at AUA2025
14 Apr 2025 11:30 GMT
… Company”), a clinical-stage biotechnology company, today announced the … efficacy of treatment with gemcitabine and docetaxel, its ease … , potential for clinical trials to deliver statistically and … FDA, failure to secure adequate sepranolone, or NDV-01 drug …
-
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone - Beyond the Abstract
11 Apr 2025 01:08 GMT
… 2B). Various treatment groups were established, including batiraxcept alone, docetaxel alone, … with either chemotherapy drug. The efficacy of these treatments was evaluated … Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol …
-
Regulatory tracker: Europe serves up earlier lymphoma nod for Roche's Columvi as final review of Eisai's Leqembi kicks off
02 Jan 2025 22:04 GMT
… Kelun-Biotech'; … treatment.
Agios Pharmaceuticals’ Pyrukynd is up for an FDA decision in … trials linked the drug';s chemo combo … after treatment.
At the trial’s 24-week treatment mark, patients on Winrevair plus other PAH medicines improved …
-
GLUT-Targeted Adhesive Nanoparticles Enhance the Oral Absorption and Anti-Tumor Effects of 2-Methoxyestradiol
14 Apr 2025 15:00 GMT
… therapeutic range, although the treatment was well tolerated.2 … and Phase II clinical trials confirmed the unsatisfactory … EDC) were purchased from Aladdin Biotechnology Co., Ltd. (Shanghai, … enhance oral delivery of docetaxel. Pharmaceutics. 2022;14(7):1361 …